CancerCompass is dedicated to provided you with the most up to date cancer information and news. Visit our website to find all our articles on Hematological Cancer News http://www.cancercompass.com/hematological-cancer-news.htm Sat, 07 Nov 2009 00:00:00 GMT Sat, 07 Nov 2009 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ Drugs used to treat psychiatric disorders are highly effective at killing cancer cells, opening up potential new lines of treatments. Dr Louise Lurze-Mann of the University of NSW School of Biotechnology and Biomolecular Sciences was talking with psychiatric researchers at the University of Queensland when they mentioned that people with diseases like schizophrenia appear to have low rates of cancer, despite being more inclined to smoke than the general population. http://www.cancercompass.com/cancer-news/article/32367.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT It's a safe bet to presume there are soup recipes in today's column because it's colder, furnaces are running and it just seems like a fall thing to do. http://www.cancercompass.com/cancer-news/article/32365.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT U.S. scientists say they have discovered a small molecule that inhibits the actions of a protein cancer cells require for survival. The researchers said they determined the molecule, called PES, inhibits a type of protein called a heat-shock protein that helps cells survive heat, lack of nutrients and other cell-damaging conditions. http://www.cancercompass.com/cancer-news/article/32368.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists. http://www.cancercompass.com/cancer-news/article/32371.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. http://www.cancercompass.com/cancer-news/article/32376.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT The Healthy Exercise for Lymphoma Patients (HELP) trial, a three-year study led by Kerry Courneya, Canada Research Chair in physical activity and cancer in the Faculty of Physical Education and Recreation, found that a regimen of aerobic exercise training produced significant improvements in physical functioning and overall quality of life benefits in patients with lymphoma. http://www.cancercompass.com/cancer-news/article/32378.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT According to recent research from the United States, Bacterial infection is the most common complication of chemotherapy-induced neutropenia particularly in patients with hematologic malignancies. Bacterial infections predominate during the initial phases of neutropenic episodes. http://www.cancercompass.com/cancer-news/article/32379.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Mollie Katzen's latest cookbook urges beginners to take on her challenge with easy recipes, such as this acorn squash entree. Use plain raw almonds, not roasted or salted, Katzen writes, and don't chop them too fine. You can cook the rice and bake the acorn squash at the same time. http://www.cancercompass.com/cancer-news/article/32356.htm CancerCompass Wed, 04 Nov 2009 00:00:00 GMT If you're watching your weight, soup can be deceptive. What could be more harmless for lunch or a light dinner? Not so fast. Depending on the recipe, some soups are full of cream and cheese, or sometimes worse, they start with a roux. In place of cream and butter, add flavor to soup with lots of vegetables, beef broth and dried and fresh herbs. http://www.cancercompass.com/cancer-news/article/32357.htm CancerCompass Wed, 04 Nov 2009 00:00:00 GMT Drink up, coffee lovers. Not only is coffee aromatic and delicious, it's good for you. Who says? None other than Harvard Medical School. Once considered questionable for your health, it turns out that the beloved beverage is actually healthful in moderation. That means a few cups a day. http://www.cancercompass.com/cancer-news/article/32341.htm CancerCompass Tue, 03 Nov 2009 00:00:00 GMT Canadian researchers say aerobic exercise benefits lymphoma patients -- even those on chemotherapy. The study, published in the Journal of Clinical Oncology, finds lymphoma patients who received exercise intervention reported significantly improved physical functioning, overall improved quality of life, less fatigue, increased happiness, less depression and an improvement in lean body mass. http://www.cancercompass.com/cancer-news/article/32335.htm CancerCompass Fri, 30 Oct 2009 00:00:00 GMT Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid. http://www.cancercompass.com/cancer-news/article/32336.htm CancerCompass Fri, 30 Oct 2009 00:00:00 GMT The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. http://www.cancercompass.com/cancer-news/article/32315.htm CancerCompass Wed, 28 Oct 2009 00:00:00 GMT People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs. A new, federally-funded study by Queen's University researchers has found that taking the drugs together is a more effective treatment than taking either of them individually. http://www.cancercompass.com/cancer-news/article/32310.htm CancerCompass Wed, 28 Oct 2009 00:00:00 GMT Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE(R) (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B- cell-like (non-GCB) diffuse large B-cell lymphoma. http://www.cancercompass.com/cancer-news/article/16477.htm CancerCompass Wed, 21 Oct 2009 00:00:00 GMT Lymphomas are the most common hematologic malignancies in the United States, accounting for up to 5% of all new cancer cases. As a group, they are the fifth leading cause of cancer deaths. Since the landmark report released in 1832 by Thomas Hodgkin, the classification of lymphomas has undergone repetitive adjustment, primarily a reflection of novel clinical and basic science discoveries. http://www.cancercompass.com/cancer-news/article/16467.htm CancerCompass Tue, 20 Oct 2009 00:00:00 GMT Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek(R) (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid. http://www.cancercompass.com/cancer-news/article/16455.htm CancerCompass Sat, 17 Oct 2009 00:00:00 GMT NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA- approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009. http://www.cancercompass.com/cancer-news/article/16445.htm CancerCompass Thu, 15 Oct 2009 00:00:00 GMT According to recent research from the United States, Context.-Lymphomas involving the breast are rare, and most cases are of B-cell lineage; T-cell neoplasms represent less than 10% of all breast lymphomas. Objective.-To define the clinicopathologic spectrum of anaplastic large cell lymphomas (ALCLs) involving the breast. http://www.cancercompass.com/cancer-news/article/16456.htm CancerCompass Sat, 17 Oct 2009 00:00:00 GMT U.S. scientists say they have discovered a group of genes that act as barriers against cancer development. Cold Spring Harbor Laboratory researchers said they used a powerful technology called RNA interference, which suppresses gene activity, to screen hundreds of candidate tumor suppressors in living mice, using small hairpin- shaped molecules that attach to specific genes and switch them off. http://www.cancercompass.com/cancer-news/article/16435.htm CancerCompass Tue, 13 Oct 2009 00:00:00 GMT